A detailed history of Tower Research Capital LLC (Trc) transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 14,765 shares of TNGX stock, worth $44,885. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,765
Previous 15,682 5.85%
Holding current value
$44,885
Previous $134,000 15.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.36 - $11.93 $6,749 - $10,939
-917 Reduced 5.85%
14,765 $113,000
Q2 2024

Aug 13, 2024

BUY
$6.66 - $10.15 $94,858 - $144,566
14,243 Added 989.78%
15,682 $134,000
Q1 2024

May 15, 2024

SELL
$7.51 - $12.88 $88,392 - $151,597
-11,770 Reduced 89.11%
1,439 $11,000
Q4 2023

Feb 13, 2024

BUY
$6.52 - $12.01 $76,681 - $141,249
11,761 Added 812.22%
13,209 $130,000
Q3 2023

Nov 14, 2023

SELL
$2.93 - $11.26 $4,163 - $16,000
-1,421 Reduced 49.53%
1,448 $16,000
Q2 2023

Aug 14, 2023

SELL
$2.67 - $4.7 $27,912 - $49,133
-10,454 Reduced 78.47%
2,869 $9,000
Q1 2023

May 09, 2023

BUY
$3.76 - $8.06 $37,979 - $81,414
10,101 Added 313.5%
13,323 $52,000
Q4 2022

Feb 10, 2023

SELL
$3.41 - $8.29 $61 - $149
-18 Reduced 0.56%
3,222 $23,000
Q3 2022

Nov 10, 2022

BUY
$3.25 - $5.46 $3,341 - $5,612
1,028 Added 46.47%
3,240 $12,000
Q2 2022

Aug 15, 2022

BUY
$3.86 - $8.01 $8,152 - $16,917
2,112 Added 2112.0%
2,212 $10,000
Q1 2022

May 12, 2022

BUY
$7.01 - $10.94 $701 - $1,094
100 New
100 $1,000
Q4 2021

Feb 14, 2022

SELL
$9.55 - $14.29 $7,907 - $11,832
-828 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$9.56 - $17.3 $7,915 - $14,324
828 New
828 $11,000

Others Institutions Holding TNGX

About Tango Therapeutics, Inc.


  • Ticker TNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,067,296
  • Market Cap $268M
  • Description
  • Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...
More about TNGX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.